Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$24.84 USD
-0.04 (-0.16%)
Updated May 24, 2024 03:59 PM ET
After-Market: $24.85 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 241 - 260 ( 278 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FY18; Quiet Year Ahead for NTLA as First IND Submission Targeted for 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL as IND for Lead ATTR Candidate Pushed Back into 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Potential Headline Risk with Pending Court Decision, LT Impact Likely Minimal
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
2Q, Continued Progress should help Close Valuation Gap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Transparency on IND Timing for ATTR, Gene Editing Progress in Other Indications
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
YE17 Financials; IND-Enabling Studies to Begin for Lead ATTR Candidate Mid-2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
ASH Presentations Highlight Gene Editing Progress in Hemoglobinopathies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.